Compound Detail
CHEMBL4297840
TISLELIZUMAB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL4297840 |
| Name | TISLELIZUMAB |
| Phase | Approved |
| Structure Type | SEQ |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
11
Known Names
20
Indications
1
Mechanisms
Drug Information
| Molecule Type | Antibody |
| First Approval | 2023 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Programmed cell death protein 1 inhibitor | INHIBITOR | Programmed cell death protein 1 | ✓ | ✓ |
Indications
Adenocarcinoma Adenocarcinoma Carcinoma, Non-Small-Cell Lung Esophageal Neoplasms Esophageal Neoplasms Esophageal Squamous Cell Carcinoma Neoplasms Neoplasms Stomach Neoplasms Stomach Neoplasms Stomach Neoplasms Breast Neoplasms Carcinoma, Hepatocellular Cholangiocarcinoma Cholangiocarcinoma Hodgkin Disease Hodgkin Disease Lymphoma, Large B-Cell, Diffuse Nasopharyngeal Carcinoma Rectal Neoplasms
ATC Classification
L01FF09
tislelizumab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Data from ChEMBL 36 via Core Engine